Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige
Latest Out-Licensing Deal Signed By Prestige BioPharma
Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.
